Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"
Article
Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.
[powerpress]
Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Article
Dr. Rosalyn Juergens, McMaster University, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
[powerpress]
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Article
Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on, and the particular markers they prioritize.
[powerpress]
Dr. David Spigel: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Article
David Spigel, Sarah Cannon Cancer Center, reviews how he discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
[powerpress]
Dr. Greg Riely: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Article
Dr. Greg Riely, from Memorial Sloan-Kettering, reviews his thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
[powerpress]
Dr. Ravi Salgia on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Article
Dr. Ravi Salgia from University of Chicago describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
[powerpress]
Dr. Sarah Goldberg: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Article
Dr. Sarah Goldberg, Yale Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
[powerpress]
Dr. Karen Reckamp on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Article
Dr. Karen Reckamp from City of Hope Cancer Center in Duarte, CA describes which patients with advanced NSCLC she seeks molecular marker testing on, and the particular markers she prioritizes.
[powerpress]
Dr. Geoffrey Oxnard on What Molecular Markers to Test for in Advanced NSCLC, and in Whom?
Article
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
[powerpress]
Dr. Leighl's Highlights in Lung Cancer from 2012: MEK Inhibitor Therapy for KRAS Mutation-Positive NSCLC
Article
The next portion of Dr. Leighl's "Highlights of Lung Cancer from 2012" webinar focused on exciting research presented at ASCO 2012 and very recently published on the potential efficacy of a new class of targeted therapy, called MEK inhibitors, for the large subset of patients who have a KRAS mutation.